Despite a pointed decision by the Federal Circuit vacating and remanding the matter to the Patent Trial and Appeal Board, yesterday the Board once again granted priority for CRISPR technology to the Broad Institute. A more detailed discussion of the basis for this judgment will follow.
Patent Law Weblog
recent posts
- USPTO Requires Foreign-domiciled Patent Applicants and Owners to Be Represented by USPTO-registered Practitioners
- Extremity Medical, LLC v. Nextremity Solutions, Inc. (Fed. Cir. 2026)
- PTAB § 101 Affirmance Rates Dip under Director Squires
- In re Magnolia Medical Technologies, Inc. (Fed. Cir. 2026)
- Improving the Abstract Idea: How a Rhetorical Move Undermines § 101 Analysis of Technical Improvements in Software Inventions
Patent Docs 
Leave a comment